Hearing loss due to urate deposition in the middle ear: A case report and literature review

Risk of Sudden Sensorineural Hearing Loss in Patients with Gout: A Population-Level Study in a South Korean National Health Screening Cohort

Background: Gout, characterized by serum uric acid accumulation, prompts inflammation, leading to tissue damage and comorbidities. Prior studies reported a higher risk of hearing loss in gout patients; however, the specific risk of sudden sensorineural hearing loss (SSNHL) remains unclear. Method: This population-based study assessed SSNHL incidence and risk in patients aged ≥ 40 years with or without gout, excluding those with prior SSNHL, within the Korean National Health Insurance Service Health Screening Cohort (2002-2019). A total of 24,508 gout patients were matched 1:4 with 98,032 controls by age, sex, income, and region. SSNHL incidence was compared, and Kaplan-Meier curves with log-rank tests evaluated cumulative incidence over 200 months. Hazard ratios (HRs) were calculated using stratified Cox models adjusted for patient characteristics. Results: SSNHL incidence was slightly higher in the gout cohort vs. controls (1.70% vs. 1.96%, SD = 0.02). Kaplan-Meier analysis revealed significantly higher cumulative SSNHL incidence in gout patients (p = 0.009). Patients with gout had a significantly higher risk of developing SSNHL in both the unadjusted (HR [95% CI]: 1.14 [1.03-1.27]; p = 0.010) and adjusted Cox models (1.13 [1.02-1.26]; p = 0.021). Subgroup analyses indicated higher risk in gout patients aged <60 years, males, non-smokers, non-drinkers, moderately-high income, normal BMI, Charlson Comorbidity Index score of 0, or fasting blood glucose < 100 mg/dL (all p < 0.05). Conclusions: Korean adults with gout, particularly younger, healthier patients, face increased SSNHL risk. Early, effective gout management may help mitigate this risk.

Nanodelivery of antioxidant Agents: A promising strategy for preventing sensorineural hearing loss

Sensorineural hearing loss (SNHL), often stemming from reactive oxygen species (ROS) generation due to various factors such as ototoxic drugs, acoustic trauma, and aging, remains a significant health concern. Oxidative stress-induced damage to the sensory cells of the inner ear, particularly the non-regenerating hair cells, is a critical pathologic mechanism leading to SNHL. Despite the proven efficacy of antioxidants in mitigating oxidative stress, their clinical application for otoprotection is hindered by the limitations of conventional drug delivery methods. This review highlights the challenges associated with systemic and intratympanic administration of antioxidants, including the blood-labyrinthine barrier, restricted permeability of the round window membrane, and inadequate blood flow to the inner ear. To overcome these hurdles, the application of nanoparticles as a delivery platform for antioxidants emerges as a promising solution. Nanocarriers facilitate indirect drug delivery to the cochlea through the round and oval window membrane, optimising drug absorption while reducing dosage, Eustachian tube clearance, and associated side effects. Furthermore, the development of nanoparticles carrying antioxidants tailored to the intracochlear environment holds immense potential. This literature research aimed to critically examine the root causes of SNHL and ROS overproduction in the inner ear, offering insights into the application of nanoparticle-based drug delivery systems for safeguarding sensorineural hair cells. By focusing on the intricate interplay between oxidative stress and hearing loss, this research aims to contribute to the advancement of innovative therapeutic strategies for the prevention of SNHL.

Middle Ear Tophi: A Case Series of Two Unusual Lesions and a Report of Facial Weakness and Review of the Literature

OBJECTIVE

Tophaceous lesions of the middle ear from calcium pyrophosphate deposition disease (CPPD, or pseudogout) and gout are infrequently reported. Recognizing its characteristic findings will allow clinicians to accurately narrow the differential diagnosis of bony-appearing middle ear lesions and improve management.

PATIENTS

Two consecutive cases of tophaceous middle ear lesions presenting to a tertiary care center between January 2021 and December 2021. Neither with previous rheumatologic history.

INTERVENTIONS

Surgical excision of tophaceous middle ear lesions.

MAIN OUTCOME MEASURE

Improvements in facial weakness and conductive hearing loss.

RESULTS

The first case was a 66-year-old gentleman with progressive conductive loss, ipsilateral progressive facial weakness over years, and an opaque, irregular-appearing tympanic membrane anterior to the malleus found to have CPPD on surgical pathology, with immediate postoperative improvement of facial function. The second was a 75-year-old gentleman with progressive conductive loss and similar appearing tympanic membrane as case 1, previously diagnosed with tympanosclerosis, found to have gout on surgical pathology. In both cases, the CT showed a heterogenous, bony-appearing lesion in the middle ear, and both tophaceous lesions were a of gritty, chalky consistency intraoperatively.

CONCLUSION

Tophaceous lesions of the middle ear are rare but have similar findings. Notably, the tympanic membrane can appear opaque and irregular, and the CT demonstrates a radiopaque, heterogeneous appearance. Facial weakness is an unusual finding. Specimens of suspected tophi must be sent to pathology without formalin for accurate diagnosis.

Case Report: A rare case of bilateral middle ear tophaceous gout

Introduction

Hypacusia can be caused by various etiologies; however, hearing loss attributed to gouty tophi remains a rare occurrence. This case report presents, for the first time, a bilateral gouty tophi causing hearing impairment.

Case presentation

This report describes a case study involving an 83-year-old Caucasian female patient who presented symptoms of hypacusia, pruritus, and a sensation of pressure in her right ear. A computed tomography scan revealed the presence of non-homogeneous calcified structures in both ears. Following a comprehensive assessment that included pure-tone audiometry and a thorough evaluation of the patient's clinical complaints, a tympanoplasty procedure was initially performed on the right ear. Pathological analysis revealed the presence of gouty tophi. After surgical removal of the tophus, a notable improvement in the patient's hearing threshold was observed. Four months later, a similar surgical intervention was performed on the contralateral ear, achieving a similar positive outcome. The substantial postoperative decrease of bone conduction indicates an inner ear affection by the gout tophi.

Conclusion

Gout tophus in both ears is a very rare but possible cause of hypacusia, even in the absence of a pre-existing diagnosis of systemic gout disease. We report a case of gout tophi in both ears as a rare cause of hearing loss.

Tophaceous Gout of the Middle Ear

Tophaceous gout can rarely present in the middle ear as a mass-like lesion, causing conductive hearing loss. Noncontrast high-resolution computed tomography (HRCT) of the temporal bone plays a significant role in the diagnosis. Awareness of this condition among radiologists is important since it presents a distinctive appearance on HRCT. We present a case of tophaceous gout of the middle ear diagnosed with photon-counting computed tomography (PCCT). Teaching point: The presence of a partially calcified mass with a semolina-like appearance within the middle ear is highly suggestive of tophaceous gout, even in the presence of normal serum uric acid levels.